Is HOOKIPA Pharma Inc. (HOOK) a Buy, Sell, or Hold?
OTC : HOOK
HOOKIPA Pharma Inc.
$1.15 USD
$0 (0.0%)
- Volume
- 0
- Average Volume
- 11.96K
- Market Capitalization
- $14.4M
- P/E Ratio
- -0.71
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $1.55
- Year Low
- $0.81
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.93
Insider Activity Summary (Last 12 Months)
Insiders Buying
15
Insiders Selling
3
Amount of Insider Selling
$42785
HOOK Insider Buying/Selling by Quarter
HOOK Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Peters Malte | director, officer: Chief Executive Officer | 2025-08-19 | S-Sale | 0.8217 | 2025-10-09 |
| Peters Malte | director, officer: Chief Executive Officer | 2025-07-22 | S-Sale | 0.92 | 2025-07-23 |
| Coelho Mary Theresa | director, officer: EVP and CFO | 2025-07-22 | S-Sale | 0.92 | 2025-07-23 |
| Coelho Mary Theresa | director, officer: EVP and CFO | 2024-07-22 | A-Award | 0 | 2024-07-24 |
| Peters Malte | director, officer: Chief Executive Officer | 2024-07-22 | A-Award | 0 | 2024-07-24 |
| Cassidy Sean A | director | 2024-07-22 | A-Award | 6.44 | 2024-07-24 |
| Cassidy Sean A | 2024-07-22 | 0 | 2024-07-24 | ||
| Peters Malte | director | 2024-06-17 | A-Award | 0.71 | 2024-06-18 |
| van de Winkel Jan | director | 2024-06-17 | A-Award | 0.71 | 2024-06-18 |
| Kaufman David Ross | director | 2024-06-17 | A-Award | 0.71 | 2024-06-18 |
| O'Neill Julie | director | 2024-06-17 | A-Award | 0.71 | 2024-06-18 |
| Coelho Mary Theresa | director | 2024-06-17 | A-Award | 0.71 | 2024-06-18 |
| Reilly Timothy P. | director | 2024-06-17 | A-Award | 0.71 | 2024-06-18 |
| Orlinger Klaus | officer: Chief Scientific Officer | 2024-04-15 | A-Award | 0.76 | 2024-04-17 |
| Aldag Jorn | director, officer: Chief Executive Officer | 2024-04-15 | A-Award | 0.76 | 2024-04-17 |
| Winderlich Mark | officer: Chief Development Officer | 2024-04-15 | A-Award | 0.76 | 2024-04-17 |
| Winderlich Mark | officer: Chief Development Officer | 2024-04-15 | A-Award | 0.76 | 2024-04-17 |
| Kandera Reinhard | director, officer: Chief Financial Officer | 2024-04-15 | A-Award | 0.76 | 2024-04-17 |
| Necina Roman | officer: Chief Operations Officer | 2024-04-15 | A-Award | 0.76 | 2024-04-17 |
| Winderlich Mark | 2024-04-01 | 0 | 2024-04-11 | ||
| GILEAD SCIENCES, INC. | 10 percent owner | 2023-12-20 | 0 | 2023-12-22 | |
| Kandera Reinhard | director, officer: Chief Financial Officer | 2023-08-21 | P-Purchase | 0.725 | 2023-08-22 |
| Kandera Reinhard | director, officer: Chief Financial Officer | 2023-08-16 | P-Purchase | 0.714 | 2023-08-17 |
| Aldag Jorn | director, officer: Chief Executive Officer | 2023-07-11 | P-Purchase | 0.8284 | 2023-07-11 |
| Aldag Jorn | director, officer: Chief Executive Officer | 2023-07-07 | P-Purchase | 0.81 | 2023-07-11 |
| Aldag Jorn | director, officer: Chief Executive Officer | 2023-07-05 | P-Purchase | 0.89 | 2023-07-07 |
| Aldag Jorn | director, officer: Chief Executive Officer | 2023-07-03 | P-Purchase | 0.8911 | 2023-07-05 |
| Kandera Reinhard | director, officer: Chief Financial Officer | 2023-06-30 | P-Purchase | 0.88 | 2023-07-03 |
| Peters Malte | director | 2023-06-09 | A-Award | 1.01 | 2023-06-09 |
| Reilly Timothy P. | director | 2023-06-09 | A-Award | 1.01 | 2023-06-09 |
| O'Neill Julie | director | 2023-06-09 | A-Award | 1.01 | 2023-06-09 |
| van de Winkel Jan | director | 2023-06-09 | A-Award | 1.01 | 2023-06-09 |
| Kaufman David Ross | director | 2023-06-09 | A-Award | 1.01 | 2023-06-09 |
| Coelho Mary Theresa | director | 2023-06-09 | A-Award | 1.01 | 2023-06-09 |
| Orlinger Klaus | officer: Chief Scientific Officer | 2023-04-14 | A-Award | 1 | 2023-04-18 |
| Necina Roman | officer: Chief Development Officer | 2023-04-14 | A-Award | 1 | 2023-04-18 |
| Schlienger Katia | officer: Chief Medical Officer | 2023-04-14 | A-Award | 1 | 2023-04-18 |
| Baker Christine D. | officer: Chief Operating Officer | 2023-04-14 | A-Award | 1 | 2023-04-18 |
| Kandera Reinhard | director, officer: Chief Financial Officer | 2023-04-14 | A-Award | 1 | 2023-04-18 |
| Aldag Jorn | director, officer: Chief Executive Officer | 2023-04-14 | A-Award | 1 | 2023-04-18 |
| Schlienger Katia | officer: Chief Medical Officer | 2023-03-09 | 0 | 2023-04-18 | |
| Schlienger Katia | officer: Chief Medical Officer | 2023-03-09 | 12 | 2023-04-18 | |
| Schlienger Katia | officer: Chief Medical Officer | 2023-03-09 | 1.66 | 2023-04-18 | |
| Peters Malte | director: | 2023-01-01 | 0 | 2023-04-18 | |
| Coelho Mary Theresa | director: | 2023-04-03 | 0 | 2023-04-04 | |
| van de Winkel Jan | director | 2022-06-30 | A-Award | 1.63 | 2022-07-01 |
| van de Winkel Jan | director: | 2022-06-30 | A-Award | 0 | 2022-07-01 |
| Reilly Timothy P. | director: | 2022-06-30 | A-Award | 0 | 2022-07-01 |
| Orlinger Klaus | officer: Chief Scientific Officer | 2022-06-30 | A-Award | 0 | 2022-07-01 |
| Orlinger Klaus | officer: Chief Scientific Officer | 2022-06-30 | A-Award | 1.66 | 2022-07-01 |
| O'Neill Julie | director: | 2022-06-30 | A-Award | 0 | 2022-07-01 |
| Necina Roman | officer: Chief Technology Officer | 2022-06-30 | A-Award | 1.66 | 2022-07-01 |
| Necina Roman | officer: Chief Technology Officer | 2022-06-30 | A-Award | 0 | 2022-07-01 |
| Matushansky Igor | officer: Chief Medical Officer | 2022-06-30 | A-Award | 0 | 2022-07-01 |
| Kelly Michael Aaron | director: | 2022-06-30 | A-Award | 0 | 2022-07-01 |
| Kaufman David Ross | director: | 2022-06-30 | A-Award | 0 | 2022-07-01 |
| Kandera Reinhard | director, officer: Chief Financial Officer | 2022-06-30 | A-Award | 1.66 | 2022-07-01 |
| Kandera Reinhard | officer: Chief Financial Officer | 2022-06-30 | A-Award | 0 | 2022-07-01 |
| Baker Christine D. | officer: Chief Operating Officer | 2022-06-30 | A-Award | 0 | 2022-07-01 |
| Aldag Jorn | director, officer: Chief Executive Officer | 2022-06-30 | A-Award | 1.66 | 2022-07-01 |
| Aldag Jorn | officer: Chief Executive Officer | 2022-06-30 | A-Award | 0 | 2022-07-01 |
| Orlinger Klaus | officer: Chief Scientific Officer | 2022-04-19 | A-Award | 1.66 | 2022-04-20 |
| Orlinger Klaus | officer: Chief Scientific Officer | 2022-04-19 | A-Award | 0 | 2022-04-20 |
| Necina Roman | officer: Chief Technology Officer | 2022-04-19 | A-Award | 1.66 | 2022-04-20 |
| Necina Roman | officer: Chief Technology Officer | 2022-04-19 | A-Award | 0 | 2022-04-20 |
| Matushansky Igor | officer: Chief Medical Officer | 2022-04-19 | A-Award | 0 | 2022-04-20 |
| Kandera Reinhard | officer: Chief Financial Officer | 2022-04-19 | A-Award | 0 | 2022-04-20 |
| Kandera Reinhard | director, officer: Chief Financial Officer | 2022-04-19 | A-Award | 1.66 | 2022-04-20 |
| Baker Christine D. | officer: Chief Business Officer | 2022-04-19 | A-Award | 0 | 2022-04-20 |
| Aldag Jorn | director, officer: Chief Executive Officer | 2022-04-19 | A-Award | 1.66 | 2022-04-20 |
| Aldag Jorn | officer: Chief Executive Officer | 2022-04-19 | A-Award | 0 | 2022-04-20 |
| Reilly Timothy P. | director: | 2022-04-15 | 0 | 2022-04-20 | |
| GILEAD SCIENCES INC | 10 percent owner | 2022-02-15 | 0 | 2022-02-17 | |
| Orlinger Klaus | officer: Executive VP, Research | 2022-02-01 | A-Award | 1.5 | 2022-02-01 |
| Orlinger Klaus | officer: Executive VP, Research | 2022-02-01 | A-Award | 3 | 2022-02-01 |
| Baker Christine D. | officer: Chief Business Officer | 2022-02-01 | A-Award | 1.5 | 2022-02-01 |
| Baker Christine D. | officer: Chief Business Officer | 2022-02-01 | A-Award | 3 | 2022-02-01 |
| Necina Roman | officer: Chief Technology Officer | 2022-02-01 | A-Award | 1.5 | 2022-02-01 |
| Necina Roman | officer: Chief Technology Officer | 2022-02-01 | A-Award | 3 | 2022-02-01 |
| Matushansky Igor | officer: Chief Medical Officer | 2022-02-01 | A-Award | 3 | 2022-02-01 |
| Matushansky Igor | officer: Chief Medical Officer | 2022-02-01 | A-Award | 1.5 | 2022-02-01 |
| Kandera Reinhard | director, officer: Chief Financial Officer | 2022-02-01 | A-Award | 1.5 | 2022-02-01 |
| Kandera Reinhard | director, officer: Chief Financial Officer | 2022-02-01 | A-Award | 3 | 2022-02-01 |
| Aldag Jorn | director, officer: Chief Executive Officer | 2022-02-01 | A-Award | 3 | 2022-02-01 |
| Aldag Jorn | director, officer: Chief Executive Officer | 2022-02-01 | A-Award | 1.5 | 2022-02-01 |
| Matushansky Igor | officer: Chief Medical Officer | 2021-12-21 | M-Exempt | 0.1 | 2022-01-12 |
| Matushansky Igor | officer: Chief Medical Officer | 2021-12-21 | M-Exempt | 0.1 | 2022-01-12 |
| Matushansky Igor | officer: Chief Medical Officer | 2021-12-21 | M-Exempt | 0.1 | 2022-01-12 |
| Matushansky Igor | officer: Chief Medical Officer | 2021-12-21 | S-Sale | 2.49 | 2022-01-12 |
| Matushansky Igor | officer: Chief Medical Officer | 2021-12-21 | S-Sale | 2.49 | 2022-01-12 |
| Matushansky Igor | officer: Chief Medical Officer | 2021-12-21 | S-Sale | 2.49 | 2022-01-12 |
| Matushansky Igor | officer: Chief Medical Officer | 2021-12-21 | M-Exempt | 0.1 | 2022-01-12 |
| Matushansky Igor | officer: Chief Medical Officer | 2021-12-21 | M-Exempt | 0.1 | 2022-01-12 |
| Matushansky Igor | officer: Chief Medical Officer | 2021-12-21 | M-Exempt | 0.1 | 2022-01-12 |
| Seghezzi Graziano | director: | 2021-06-01 | 0 | 2021-06-14 | |
| van de Winkel Jan | director | 2021-06-01 | A-Award | 16.61 | 2021-06-04 |
| Soria Jean-Charles | director | 2021-06-01 | A-Award | 16.61 | 2021-06-04 |
| Seghezzi Graziano | director | 2021-06-01 | A-Award | 16.61 | 2021-06-04 |
| O'Neill Julie | director | 2021-06-01 | A-Award | 16.61 | 2021-06-04 |
| Lengauer Christoph | director | 2021-06-01 | A-Award | 16.61 | 2021-06-04 |